AlzeCure Pharma (ALZCUR) - Net Assets
Based on the latest financial reports, AlzeCure Pharma (ALZCUR) has net assets worth Skr50.66 Million SEK (≈ $5.45 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr66.59 Million ≈ $7.17 Million USD) and total liabilities (Skr15.93 Million ≈ $1.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of AlzeCure Pharma for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr50.66 Million |
| % of Total Assets | 76.08% |
| Annual Growth Rate | -9.29% |
| 5-Year Change | -76.36% |
| 10-Year Change | N/A |
| Growth Volatility | 136.85 |
AlzeCure Pharma - Net Assets Trend (2017–2024)
This chart illustrates how AlzeCure Pharma's net assets have evolved over time, based on quarterly financial data. Also explore AlzeCure Pharma (ALZCUR) total assets for the complete picture of this company's asset base.
Annual Net Assets for AlzeCure Pharma (2017–2024)
The table below shows the annual net assets of AlzeCure Pharma from 2017 to 2024. For live valuation and market cap data, see market value of AlzeCure Pharma.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr26.18 Million ≈ $2.82 Million |
+10.14% |
| 2023-12-31 | Skr23.77 Million ≈ $2.56 Million |
-60.69% |
| 2022-12-31 | Skr60.48 Million ≈ $6.51 Million |
+83.42% |
| 2021-12-31 | Skr32.97 Million ≈ $3.55 Million |
-70.23% |
| 2020-12-31 | Skr110.75 Million ≈ $11.92 Million |
-39.15% |
| 2019-12-31 | Skr182.01 Million ≈ $19.59 Million |
-21.94% |
| 2018-12-31 | Skr233.17 Million ≈ $25.09 Million |
+349.92% |
| 2017-12-31 | Skr51.83 Million ≈ $5.58 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AlzeCure Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36463000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.21 Million | 8.43% |
| Other Components | Skr399.43 Million | 1525.42% |
| Total Equity | Skr26.18 Million | 100.00% |
AlzeCure Pharma Competitors by Market Cap
The table below lists competitors of AlzeCure Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Smart Concrete Public Company Limited
BK:SMART
|
$18.18 Million |
|
N Citron Inc
KQ:101400
|
$18.18 Million |
|
Eureka Design Public Company Limited
BK:UREKA
|
$18.19 Million |
|
Allarity Therapeutics Inc
NASDAQ:ALLR
|
$18.19 Million |
|
Koonenberry Gold Ltd
AU:KNB
|
$18.17 Million |
|
Kritika Wires Limited
NSE:KRITIKA
|
$18.17 Million |
|
Delta Resources Ltd
V:DLTA
|
$18.17 Million |
|
Mitchells & Butlers PLC
LSE:MAB
|
$18.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AlzeCure Pharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 23,774,000 to 26,185,000, a change of 2,411,000 (10.1%).
- Net loss of 35,234,000 reduced equity.
- Share repurchases of 44,554,000 reduced equity.
- New share issuances of 44,554,000 increased equity.
- Other factors increased equity by 37,645,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-35.23 Million | -134.56% |
| Share Repurchases | Skr44.55 Million | -170.15% |
| Share Issuances | Skr44.55 Million | +170.15% |
| Other Changes | Skr37.65 Million | +143.77% |
| Total Change | Skr- | 10.14% |
Book Value vs Market Value Analysis
This analysis compares AlzeCure Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.54x to 4.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr2.74 | Skr1.47 | x |
| 2018-12-31 | Skr9.83 | Skr1.47 | x |
| 2019-12-31 | Skr4.63 | Skr1.47 | x |
| 2020-12-31 | Skr2.82 | Skr1.47 | x |
| 2021-12-31 | Skr0.84 | Skr1.47 | x |
| 2022-12-31 | Skr1.27 | Skr1.47 | x |
| 2023-12-31 | Skr0.38 | Skr1.47 | x |
| 2024-12-31 | Skr0.34 | Skr1.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AlzeCure Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -134.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.32x
- Recent ROE (-134.56%) is below the historical average (-93.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -20.88% | -1225.06% | 0.02x | 1.08x | Skr-16.00 Million |
| 2018 | -15.43% | 0.00% | 0.00x | 1.02x | Skr-59.30 Million |
| 2019 | -28.02% | 0.00% | 0.00x | 1.03x | Skr-69.21 Million |
| 2020 | -64.44% | 0.00% | 0.00x | 1.06x | Skr-82.44 Million |
| 2021 | -235.89% | 0.00% | 0.00x | 1.38x | Skr-81.08 Million |
| 2022 | -92.65% | 0.00% | 0.00x | 1.17x | Skr-62.08 Million |
| 2023 | -156.33% | 0.00% | 0.00x | 1.35x | Skr-39.54 Million |
| 2024 | -134.56% | 0.00% | 0.00x | 1.32x | Skr-37.85 Million |
Industry Comparison
This section compares AlzeCure Pharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $198,480,697
- Average return on equity (ROE) among peers: -93.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AlzeCure Pharma (ALZCUR) | Skr50.66 Million | -20.88% | 0.31x | $18.18 Million |
| 2cureX AB (2CUREX) | $8.19 Million | -5.85% | 0.47x | $4.90 Million |
| Ascelia Pharma AB (publ) (ACE) | $236.06 Million | -41.81% | 0.08x | $40.96 Million |
| AcouSort AB (ACOU) | $5.92 Million | -163.51% | 0.36x | $8.97 Million |
| Active Biotech AB (ACTI) | $30.67 Million | -149.35% | 0.44x | $17.19 Million |
| Alzinova AB (ALZ) | $947.42K | -195.83% | 0.18x | $4.97 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $11.24 Million |
| Alligator Bioscience AB (ATORX) | $115.24 Million | -124.61% | 0.32x | $14.33 Million |
| BioInvent International AB (BINV) | $1.31 Billion | -25.22% | 0.07x | $155.44 Million |
| BioArctic AB (publ) (BIOA-B) | $60.76 Million | 94.77% | 10.65x | $2.59 Billion |
About AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sl… Read more